Jeffrey P. Gregg's research laboratory has been dedicated to understanding the genetic basis of cancer using two fundamental biological processes, the genetic predisposition for cancer and molecular alterations (changes in DNA, gene expression and protein) that occur in individual tumors.
In searching for common genetic modifiers of cancer at the DNA level, Gregg has examined links between polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer. He used innovative technology and informatics to study complex somatic changes in tumor formation, understand the underlying biology of cancer, and define better predictors for prognosis and responsiveness to clinical adjuvant modalities.
Dr. Gregg, an expert in microarray technology, has also moved into the neurosciences and research on autism. He has taken a unique approach to studying autism that uses microarray technology to perform gene expression studies of the entire genome of peripheral lymphocytes in order to identify genes associated with autism.
In addition to these microarray studies, he is adapting microarray technology to identify gains and losses (i.e., duplications and deletions) in the genome of children with autism.
Director of Gene Expression Shared Resource
Director of Molecular Diagnostics
2805 50th Street, Suite 2418
Sacramento, CA 95817
B.A., UC San Diego, La Jolla, California, 1989
Select Recent Publications:
Gosselin R, Dager W, Roberts A, Freeman L, Gandy L, Gregg J, Dwyre D. Effect of telavancin (Vibativ) on routine coagulation test results. Am J Clin Pathol. 2011 Dec;136(6):848-54.
Lavenex P, Sugden SG, Davis RR, Gregg JP, Lavenex PB. Developmental regulation of gene expression and astrocytic processes may explain selective hippocampal vulnerability. Hippocampus. 2011 Feb;21(2):142-9. doi: 10.1002/hipo.20730.
Stamova B, Green PG, Tian Y, Hertz-Picciotto I, Pessah IN, Hansen R, Yang X, Teng J, Gregg JP, Ashwood P, Van de Water J, Sharp FR. Correlations between gene expression and mercury levels in blood of boys with and without autism. Neurotox Res. 2011 Jan;19(1):31-48. Epub 2009 Nov 24.
Tian Y, Green PG, Stamova B, Hertz-Picciotto I, Pessah IN, Hansen R, Yang X, Gregg JP, Ashwood P, Jickling G, Van de Water J, Sharp FR. Correlations of gene expression with blood lead levels in children with autism compared to typically developing controls. Neurotox Res. 2011 Jan;19(1):1-13.
Bannasch D, Young A, Myers J, Truv? K, Dickinson P, Gregg J, Davis R, Bongcam-Rudloff E, Webster MT, Lindblad-Toh K, Pedersen N. Localization of canine brachycephaly using an across breed mapping approach. PLoS One. 2010 Mar 10;5(3):e9632.
Stamova BS, Apperson M, Walker WL, Tian Y, Xu H, Adamczy P, Zhan X, Liu DZ, Ander BP, Liao IH, Gregg JP, Turner RJ, Jickling G, Lit L, Sharp FR. Identification and validation of suitable endogenous reference genes for gene expression studies in human peripheral blood. BMC Med Genomics. 2009 Aug 5;2:49.
Liu DZ, Cheng XY, Ander BP, Xu H, Davis RR, Gregg JP, Sharp FR. Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons. Neurobiol Dis. 2008 May;30(2):201-11. Epub 2008 Feb 9.
Xu H, Tang Y, Liu DZ, Ran R, Ander BP, Apperson M, Liu XS, Khoury JC, Gregg JP, Pancioli A, Jauch EC, Wagner KR, Verro P, Broderick JP, Sharp FR. Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of ischemic stroke. J Cereb Blood Flow Metab. 2008 Jul;28(7):1320-8.
Denning L, Anderson JA, Davis R, Gregg JP, Kuzdenyi J, Maselli RA. High throughput genetic analysis of congenital myasthenic syndromes using resequencing microarrays. PLoS One. 2007 Sep 19;2(9):e918.
Damonte P, Gregg JP, Borowsky AD, Keister BA, Cardiff RD. EMT tumorigenesis in the mouse mammary gland. Lab Invest. 2007 Dec;87(12):1218-26. Epub 2007 Oct 8.